OrbiMed executives acquire $499,984 worth of BiomX Inc. warrants
PHGE
+1.22%
Add to/Remove from Watchlist
Add to Watchlist
Add Position
Position added successfully to:
Please name your holdings portfolio
Type:
BUY
SELL
Date:
Amount:
Price
Point Value:
Leverage:
1:1
1:10
1:25
1:50
1:100
1:200
1:400
1:500
1:1000
Commission:
Create New Watchlist
Create
Create a new holdings portfolio
Add
Create
+ Add another position
Close
Executives from OrbiMed, a leading investment firm in the healthcare sector, have recently made significant purchases of derivative securities from BiomX Inc. (NYSE:PHGE), a company specializing in biological products. This move indicates a bolstered interest in the biotech firm’s future potential.
The transactions, which took place on March 15, 2024, involved OrbiMed Israel BioFund GP Limited Partnership and OrbiMed Israel GP Ltd., both of which are connected to OrbiMed. Carl L. Gordon and Erez Chimovits, who are associated with the investment committee of OrbiMed, were key figures in these transactions.
The executives acquired warrants that allow them to buy shares of BiomX Inc. These warrants were bought at prices ranging up to $0.2311 each, totaling approximately $499,984. The warrants are exercisable following the approval of BiomX’s stockholders and are subject to certain ownership limitations. Specifically, the warrants cannot be exercised if doing so would result in the holder owning more than 19.9% of BiomX’s outstanding common stock.
As per the filing, each warrant provides the right to purchase one share of BiomX’s common stock. The warrants are part of a private placement and come with an expiration date set for 24 months after they become exercisable.
The accumulation of warrants by OrbiMed executives is a transaction of note for investors, as it reflects confidence by seasoned investors in the future prospects of BiomX Inc. It is also indicative of the investment strategy employed by OrbiMed in securing influential positions within companies they consider to have substantial growth potential.
The executed transactions were disclosed in compliance with SEC regulations, and the details were made public on March 19, 2024. The filings provide a transparent view of the investment activities of OrbiMed’s executives, underscoring their ongoing commitment to and belief in BiomX Inc. as a valuable entity in the biotech industry.
InvestingPro Insights
Following the recent transactions by OrbiMed executives, a closer look at BiomX Inc. (NYSE:PHGE) through InvestingPro’s data and analytics offers a nuanced perspective on the company’s financial health and market potential. BiomX’s current Market Cap stands at $16.67 million, reflecting its position in the biotech market. Despite a challenging financial performance with an Adjusted P/E Ratio over the last twelve months as of Q3 2023 at -0.63, the company’s stock has demonstrated a strong return over the last month, with a 60.62% increase. This suggests a potential shift in investor sentiment or market dynamics that could be of interest to prospective investors.
Two InvestingPro Tips that could be particularly relevant for investors considering BiomX are its cash position and recent price performance. BiomX holds more cash than debt on its balance sheet, which could provide some financial flexibility in the near term. Additionally, the company has seen a strong return over the last three months, with a 33.11% increase, which could signal growing investor confidence or a positive reaction to company developments.
For those looking to delve deeper into BiomX’s financials and future outlook, InvestingPro provides a comprehensive suite of additional tips. There are currently 9 more InvestingPro Tips available, which can be accessed by visiting https://www.investing.com/pro/PHGE. These tips offer valuable insights that can help inform investment decisions. To get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, use the coupon code PRONEWS24.
